Cumulative mean change procedure: application to a comparative trial of venlafaxine, imipramine, and placebo in the treatment of major depression

A R Entsuah; M M Bradley; G S Littman

doi:10.1016/0278-5846(94)90077-9

Cumulative mean change procedure: application to a comparative trial of venlafaxine, imipramine, and placebo in the treatment of major depression

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):695-706. doi: 10.1016/0278-5846(94)90077-9.

Authors

A R Entsuah¹, M M Bradley, G S Littman

Affiliation

¹ Wyeth-Ayerst Research, Radnor, PA.

PMID: 7938560
DOI: 10.1016/0278-5846(94)90077-9

Abstract

1. A simple summary measure--namely, cumulative mean change (CMC)--is proposed for analyzing incomplete repeated measures in clinical settings. 2. A simple test statistic that uses the correlation between subject responses was derived and applied to a study comparing an investigational antidepressant, venlafaxine, with imipramine and placebo. 3. The global fashion in which CMC captured all data confirmed the efficacy advantage of venlafaxine over the two control agents.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Adult
Analysis of Variance
Antidepressive Agents, Second-Generation / therapeutic use*
Cyclohexanols / therapeutic use*
Data Interpretation, Statistical*
Depressive Disorder / drug therapy*
Depressive Disorder / psychology
Double-Blind Method
Female
Humans
Imipramine / therapeutic use*
Male
Psychiatric Status Rating Scales
Venlafaxine Hydrochloride

Substances

Antidepressive Agents, Second-Generation
Cyclohexanols
Venlafaxine Hydrochloride
Imipramine